萨尔科佩尼亚和:分子机制和治疗干预措施
Tiantian Wang1,2,3, Dong Zhou1,2,3, Zhen Hong1,2,3
1Department of Neurology West China Hospital of Sichuan University Chengdu Sichuan China.
MedComm
|January 7, 2025
概括
麻症 (与年龄相关的肌肉损失) 和缓解症 (严重的消耗) 共有机制,但有所不同. 了解这些肌肉消耗疾病是开发新治疗方法的关键.
科学领域:
- 老年学是一门学科.
- 肌肉生理学 肌肉生理学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 萨尔科佩尼亚是与年龄相关的肌肉衰竭;缓解症是与癌症等疾病相关的严重衰竭.
- 这些情况涉及肌肉和脂肪组织之间的复杂相互作用,具有不同的潜在机制.
- 常规的营养支持往往不足以缓冲症.
研究的目的:
- 审查肌肉微环境在肉症和硬性硬化症中的作用.
- 讨论这些肌肉消耗疾病的当前和新兴治疗策略.
- 突出研究和治疗研究和治疗中理解萨尔科佩尼亚和缓解症之间的相互作用和区别的重要性.
主要方法:
- 关于萨尔科佩尼亚和卡切西亚的文献综述 病原性.
- 对治疗方法的分析,包括生活方式,营养和药理干预措施.
- 探索新的策略,如基因编辑,干细胞疗法和微生物组调制.
主要成果:
- 肌肉微环境的变化是萨尔科佩尼亚和卡切西亚的核心原因.
- 多式调节干预措施显示出解决这些复杂条件的前景.
- 新兴疗法为治疗开发提供了新的途径.
结论:
- 区分和理解萨尔科佩尼亚和缓解症的机制对于推进研究至关重要.
- 需要创新的治疗策略来有效地管理这些衰弱的肌肉消耗综合征.
- 对多式联络干预措施的进一步研究可以改善患者的治疗结果.
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Overview of Protein Metabolism
473
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
473
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.2K
Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
Cross-bridge Cycle
115.6K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
115.6K


